Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date.
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation / Fornaro, Michele; Martino, Matteo; Battaglia, Florinda; Colicchio, Salvatore; Perugi, Giulio. - In: NEUROPSYCHIATRIC DISEASE AND TREATMENT. - ISSN 1178-2021. - 7:(2011), p. 51-6. [10.2147/NDT.S16382]
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Fornaro, Michele;Martino, Matteo;
2011
Abstract
Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date.| File | Dimensione | Formato | |
|---|---|---|---|
|
Full-text FINALE.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
156.34 kB
Formato
Adobe PDF
|
156.34 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
